iTind (implant for enlarged prostate)

2023: Product Announcement

On July 12, 2023, Olympus announced the release of the iTind solution, a specialized implant for the treatment of enlarged prostate, or benign prostatic hyperplasia (BPH).

The iTind technology provides for a minimally invasive procedure. It involves placing a temporary implantable nitinol device that changes the shape of the prostate gland. The procedure can also be performed on an outpatient basis. The implant is in place for five to seven days while the patient stays at home. After removal of the article, effective relief of BPH-related symptoms is observed. This method is an alternative to pharmaceutical therapy, surgery and permanent implants.

iTind implant

Therapy with iTind technology is said to show significant improvement in symptoms. In particular, there was a 45.3% decrease in IPSS (BPH severity scale) and a 45.1% improvement in IPSS-QoL (quality of life) from baseline - up to 79 months after the procedure. After 36 months of follow-up, no late postoperative complications were reported and no patients required additional medical treatment. At the same time, the frequency of repeated surgical interventions at 36 months after the therapy was 4%, and the total cumulative frequency of repeated interventions from baseline during the period up to 79 months was 11.1%.

Olympus states that data from a long-term study show that the iTind procedure leads to a significant and persistent reduction in BPH-related lower urinary tract symptoms and improvement in IPSS for more than 50 months (over four years) after therapy - up to 79 months (6.6 years).^[1]

Notes